ReviewACS omega2025
Application of Gene Editing Technology Based on Targeted Delivery Materials in TNBC.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- Targeting Autophagy to Overcome Chemoresistance and Immune Resistance in Triple-Negative Breast Cancer.Cancers · 2026Review
- AMarine drugs · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, lacking the expression of estrogen receptor, progesterone receptor, and HER2, which leads to poor prognosis and limited treatment options. Despite advances in targeted therapies, TNBC patients often fail to benefit due to its heterogeneity, drug resistance, and immune evasion. Gene editing technologies such as CRISPR/Cas9 and RNA interference offer promising strategies for precise gene modulation, yet their clinical translation is challenged by delivery efficiency, off-target effects, and safety concerns. This review systematically summarizes key regulatory genes implicated in TNBC progression, including those involved in invasion, proliferation, and chemoresistance, such as BRCA1/2, TP53, MUC1, EGFR, MYC, and others. We further discuss advances in gene editing tools and their combination with targeted delivery materialsranging from viral vectors (AAV, lentivirus) to nonviral platforms (lipid nanoparticles, polymer-based systems, and bioderived vesicles)highlighting their potential to enhance editing specificity, minimize immune response, and overcome tumor microenvironment barriers. Finally, we address biosafety, ethical concerns, and mitigation strategies such as high-fidelity Cas9 variants and AI-assisted off-target prediction. Collectively, this review provides a comprehensive framework for future research and clinical application of targeted gene editing in TNBC, aiming to develop safer, more effective, and personalized treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.